blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3718544

EP3718544 - COMBINATION [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  16.06.2023
Database last updated on 31.08.2024
FormerExamination is in progress
Status updated on  24.12.2021
FormerRequest for examination was made
Status updated on  16.04.2021
FormerThe application has been published
Status updated on  04.09.2020
Most recent event   Tooltip16.06.2023Withdrawal of applicationpublished on 19.07.2023  [2023/29]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2020/41]
Inventor(s)01 / CORNFELD, Mark J.
1250 South Collegeville Road
Collegeville, PA Pennsylvania 19426 / US
02 / KUMAR, Rakesh
1250 South Collegeville Road
Collegeville, PA Pennsylvania 19426 / US
03 / MORRIS, Shannon Renae
5 Moore Drive
Research Triangle Park, NC North Carolina 27709 / US
 [2020/41]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2020/41]Ammelburg, Jan Moritz
c/o Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
Application number, filing date20160587.001.10.2014
[2020/41]
Priority number, dateUS201361885049P01.10.2013         Original published format: US 201361885049 P
US201461933379P30.01.2014         Original published format: US 201461933379 P
[2020/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3718544
Date:07.10.2020
Language:EN
[2020/41]
Search report(s)(Supplementary) European search report - dispatched on:EP22.07.2020
ClassificationIPC:A61K31/4155, A61K31/4375, A61K31/58, A61K45/06, A61P35/00, A61P35/04, A61P43/00
[2020/41]
CPC:
A61K31/58 (EP,KR,MX,US); A61K31/4155 (EP,KR,MX,US); A61K31/4196 (KR);
A61K31/4375 (EP,KR,MX,US); A61K45/06 (EP,KR,MX,US); A61P13/08 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P43/00 (EP); A61K2300/00 (KR) (-)
C-Set:
A61K31/4155, A61K2300/00 (US,EP);
A61K31/4375, A61K2300/00 (US,EP);
A61K31/58, A61K2300/00 (EP,US);
A61K31/58, A61K2300/00, A61K31/4155, A61K2300/00, A61K31/4375, A61K2300/00 (MX)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/20]
Former [2020/41]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:KOMBINATION[2020/41]
English:COMBINATION[2020/41]
French:COMBINAISON[2020/41]
Examination procedure06.04.2021Examination requested  [2021/20]
06.04.2021Date on which the examining division has become responsible
30.06.2021Amendment by applicant (claims and/or description)
04.01.2022Despatch of a communication from the examining division (Time limit: M06)
04.08.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.10.2022Reply to a communication from the examining division
07.06.2023Application withdrawn by applicant  [2023/29]
Parent application(s)   TooltipEP14790343.9  / EP3052097
Divisional application(s)EP23175752.7
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
12.10.2022Request for further processing filed
12.10.2022Full payment received (date of receipt of payment)
Request granted
20.10.2022Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
30.06.2021Request for further processing filed
30.06.2021Full payment received (date of receipt of payment)
Request granted
09.07.2021Decision despatched
Fees paidRenewal fee
29.06.2020Renewal fee patent year 03
29.06.2020Renewal fee patent year 04
29.06.2020Renewal fee patent year 05
29.06.2020Renewal fee patent year 06
01.07.2020Renewal fee patent year 07
27.10.2021Renewal fee patent year 08
27.10.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2008051380  (AUERBACH ALAN H [US], et al) [A] 1-15 * paragraph [0008] - paragraph [0017] * * paragraph [0057]; claims 1-29 *;
 [A]WO2010149755  (NOVARTIS AG [CH], et al) [A] 1-15* page 26, line 14 - page 27, line 18; example 58 *;
 [Y]WO2012135759  (GENENTECH INC [US], et al) [Y] 1-15 * page 4, line 13 - line 16; figures 1,2; claims 1-15 *;
 [Y]WO2012135750  (GENENTECH INC [US], et al) [Y] 1-15 * page 4, line 11 - line 30; claims 1-15 *;
 [Y]WO2013079964  (ASTRAZENECA AB [SE], et al) [Y] 1-15 * page 8, line 3 - line 12; claims 1-17 *;
 [A]  - J. M. CLARKE ET AL, "Novel Therapies for the Treatment of Advanced Prostate Cancer", CURRENT TREATMENT OPTIONS IN ONCOLOGY, (20130116), vol. 14, no. 1, doi:10.1007/s11864-012-0222-4, ISSN 1527-2729, pages 109 - 126, XP055152755 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1007/s11864-012-0222-4
 [A]  - LINA YIN ET AL, "Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, (20130704), vol. 14, no. 7, doi:10.3390/ijms140713958, ISSN 1661-6596, pages 13958 - 13978, XP055115967 [A] 1-15 * abstract * * page 13959, Section 2 * * Conclusions *

DOI:   http://dx.doi.org/10.3390/ijms140713958
 [A]  - F. DAYYANI ET AL, "Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer", JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE, (20111116), vol. 103, no. 22, doi:10.1093/jnci/djr362, ISSN 0027-8874, pages 1665 - 1675, XP055089916 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1093/jnci/djr362
by applicantUS5604213
 US5681835
 US5877219
 US6207716
 US6268391
 WO2008098104
 US7576209
 US2010197754
    - RINI, B.I.SMALL, E.J., "Hormone-refractory prostate cancer", Curr.Treat. Options Oncol., (20020000), vol. 3, page 437
    - SINGH, P.YAM, M.RUSSELL, P.J.KHATRI, A., "Molecular and traditional chemotherapy: a united front against prostate cancer", Cancer Lett., (20100000), vol. 293, page 1
    - SAMUELS YERICSON K, "Oncogenic PI3K and its role in cancer", Current Opinion in Oncology, (20060000), vol. 18, doi:10.1097/01.cco.0000198021.99347.b9, pages 77 - 82, XP009172157

DOI:   http://dx.doi.org/10.1097/01.cco.0000198021.99347.b9
    - J. Q. CHEUNG et al., Proc. Natl. Acad. Sci. U.S.A., (19920000), vol. 89, pages 9267 - 9271
    - J. Q. CHEUNG et al., Proc. Natl. Acad. Sci. U. S.A., (19960000), vol. 93, pages 3636 - 3641
    - NAKATANI et al., J. Biol.Chem., (19990000), vol. 274, pages 21528 - 21532
    - BELLACOSA et al., Int. J. Cancer, (19950000), vol. 64, pages 280 - 285
    - SUN, Am. J. Pathol., (20010000), vol. 159, pages 431 - 7
    - LI et al., Science, (19970000), vol. 275, pages 1943 - 1947
    - STAMBOLIC et al., Cell, (19980000), vol. 95, pages 29 - 39
    - SUN et al., Proc. Nati. Acad. Sci. U.S.A., (19990000), vol. 96, pages 6199 - 6204
    - LIAW et al., Nature Genetics, (19970000), vol. 16, pages 64 - 67
    - RISINGER et al., Cancer Research, (19970000), vol. 57, pages 4736 - 4738
    - Pharmaceutical Research, (19860000), vol. 3, no. 6, page 318
    - The Journal of Steroid Biochemistry and Molecular Biology, (20120000), vol. 129, no. 3-5, pages 115 - 28
    - "New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the American society of clinical oncology", Rev Urol, (20080530), vol. 10, no. 4, pages 294 - 6
    - MARKMAN et al., Yale Journal of Biology and Medicine, (19910000), vol. 64, page 583
    - MCGUIRE et al., Ann. Intem, Med., (19890000), vol. 111, page 273
    - HOLMES et al., J. Nat. Cancer Inst., (19910000), vol. 83, page 1797
    - EINZIG, Proc. Am. Soc. Clin. Oncol., vol. 20, page 46
    - FORASTIRE, Sem. Oncol., (19900000), vol. 20, page 56
    - WOO, Nature, (19940000), vol. 368, page 750
    - KEARNS, C.M., Seminars in Oncology, (19950000), vol. 3, no. 6, pages 16 - 23
    - ROSANIA et al., Exp. Opin. Ther. Patents, (20000000), vol. 10, no. 2, pages 215 - 230
    - SHAWVER et al., DDT, (19970200), vol. 2, no. 2
    - SINH, S.COREY, S.J., Journal of Hematotherapy and Stem Cell Research, (19990000), vol. 8, no. 5, pages 465 - 80
    - BOLEN, J.B.BRUGGE, J.S., Annual review of Immunology, (19970000), vol. 15, pages 371 - 404
    - SMITHGALL, T.E., Journal of Pharmacological and Toxicological Methods, (19950000), vol. 34, no. 3, pages 125 - 32
    - YAMAMOTO, T.TAYA, S.KAIBUCHI, K., Journal of Biochemistry, (19990000), vol. 126, no. 5, pages 799 - 803
    - BRODT, PSAMANI, A.NAVAB, R., Biochemical Pharmacology, (20000000), vol. 60, pages 1101 - 1107
    - MASSAGUE, J.WEIS-GARCIA, F., Cancer Surveys, (19960000), vol. 27, pages 41 - 64
    - PHILIP, P.A.HARRIS, A.L., Cancer Treatment and Research, (19950000), vol. 78, pages 3 - 27
    - LACKEY, K. et al., Bioorganic and Medicinal Chemistry Letters, (20000000), vol. 10, pages 223 - 226
    - MARTINEZ-LACACI, L. et al., Int. J. Cancer, (20000000), vol. 88, no. 1, pages 44 - 52
    - ABRAHAM, R.T., Current Opinion in Immunology, (19960000), vol. 8, no. 3, pages 412 - 8
    - CANMAN, C.E.LIM, D.S., Oncogene, (19980000), vol. 17, no. 25, pages 3301 - 3308
    - JACKSON, S.P., International Journal of Biochemistry and Cell Biology, (19970000), vol. 29, no. 7, pages 935 - 8
    - ZHONG, H. et al., Cancer res, (20000000), vol. 60, no. 6, pages 1541 - 1545
    - SCHAROVSKY, O.G.ROZADOS, V.R.GERVASONI, S.I.MATAR, P., Journal of Biomedical Science, (20000000), vol. 7, no. 4, pages 292 - 8
    - ASHBY, M.N., Current Opinion in Lipidology, (19980000), vol. 9, no. 2, pages 99 - 102
    - BioChim. Biophys. Acta, vol. 1423, no. 3, pages 19 - 30
    - GREEN, M.C. et al., "Monoclonal Antibody Therapy for Solid Tumors", Cancer Treat. Rev., (20000000), vol. 26, no. 4, doi:10.1053/ctrv.2000.0176, pages 269 - 286, XP009019784

DOI:   http://dx.doi.org/10.1053/ctrv.2000.0176
    - "Tyrosine Kinase Signalling in Breast cancer:erbB Family Receptor Tyrosine Kinases", Breast cancer Res., (20000000), vol. 2, no. 3, pages 176 - 183
    - BREKKEN, R.A. et al., "Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice", Cancer Res., (20000000), vol. 60, pages 5117 - 5124, XP002340113
    - BALL et al., Progress in Cell Cycle Res., (19970000), vol. 3, page 125
    - RICHON et al., Proc. Nat Acad. Sci. U.S.A., (20000000), vol. 97, no. 18, pages 10014 - 10019
    - VIGUSHIN et al., Anticancer Drugs, (20020100), vol. 13, no. 1, pages 1 - 13
    - MARKS et al., Nature Biotechnology, (20070000), vol. 25, pages 84 - 90
    - STENGER, Community Oncology, (20070000), vol. 4, pages 384 - 386
    - VINODHKUMAR et al., Biomedicine & Pharmacotherapy, (20080000), vol. 62, pages 85 - 93
    - Drugs of the Future, (20070000), vol. 32, no. 4, pages 315 - 322
    - GOTTLICHER et al., EMBO J., (20010000), vol. 20, no. 24, pages 6969 - 6978
    - BALASUBRAMANIAN et al., Cancer Letters, (20090000), vol. 280, pages 211 - 221
    - BERTRAND, European Journal of Medicinal Chemistry, (20100000), vol. 45, pages 2095 - 2116
    - ADAMS JKAUFFMAN M, Cancer Invest, (20040000), vol. 22, no. 2, pages 304 - 11
    - BOUMA et al., J. Antimicrob. Chemother., (19980000), vol. 42, no. 6, pages 817 - 20
    - WILLIAMSON et al., The Journal of Allergy and Clinical Immunology, (20061200), vol. 118, no. 6, pages 1369 - 74
    - FELING, Angew. Chem. Int. Ed. Engl., (20030000), vol. 42, no. 3, pages 355 - 7
    - KUHN DJ et al., Blood, (20070000), vol. 110, pages 3281 - 3290
    - JIA W, Blood, (20030901), vol. 102, no. 5, pages 1824 - 32
    - LEE et al., Mol Cell Endocrinol., (20020000), vol. 188, pages 47 - 54
    - D. A. TENNANT, Nature Reviews, (20100000), vol. 267
    - P. LEDER, Cancer Cell, (20060000), vol. 9, page 425
    - ALII et al., Oncogene, (20050000), vol. 24, pages 39 - 46
    - LIU, Q et al., Human Mutation, (20040000), vol. 23, pages 426 - 436
    - CHOUTALALAY, Advances in Enzyme Regulation, (19840000), vol. 22, pages 37 - 55
    - BERENBAUM, MC, Adv. Cancer Research, (19810000), vol. 35, pages 269 - 335
 WO2008US53269
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.